New approaches in metastatic melanoma: biological and molecular targeted therapies

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14737140.7.5.701PMID 17492933
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.

  2007cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• Adoptive immunotherapy for cancer: building on success

  2006cited by this paper
• The novel MEK inhibitor AZD6244/ARRY142886 inhibits the growth of melanomas harboring the BRAFV600E mutation in vitro and in vivo

  2006cited by this paper
• Improving drug penetration in tumors by targeting tumor vascularization

  2006cited by this paper
• Human T cell responses against melanoma.

  2006cited by this paper
• Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

  2006cited by this paper
• Upregulated expression of the Y-box binding protein 1 (YB-1) in melanoma cells enforces melanoma cell proliferation, survival and invasion and increases chemoresistance

  2006cited by this paper
• A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination1

  2006cited by this paper
• Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma

  2006cited by this paper
• Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo.

  2006cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

  2006cited by this paper
• Efficiency of recombinant human TNF in human cancer therapy.

  2006cited by this paper
• Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.

  2006cited by this paper
• c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage*

  2006cited by this paper
• Enhanced Immunogenicity of Heat Shock Protein 70 Peptide Complexes from Dendritic Cell-Tumor Fusion Cells1

  2006cited by this paper
• Combined targeting of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment

  2006cited by this paper
• Immunization of melanoma patients with tumor antigens recognized by T lymphocytes, using peptides and a recombinant protein encoded by MAGE-A3

  2006cited by this paper
• Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM)

  2006cited by this paper
• A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging

  2006cited by this paper
• Melanoma chondroitin sulfate proteoglycan promotes anchorage-independent growth of melanoma cells through activation of Erk1/2

  2006cited by this paper
• Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

  2006cited by this paper
• Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma

  2006cited by this paper
• MITF: master regulator of melanocyte development and melanoma oncogene.

  2006cited by this paper
• Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma

  2006cited by this paper
• Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy

  2006cited by this paper
• Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients.

  2006cited by this paper
• New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1

  2006cited by this paper
• The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

  2006cited by this paper
• CD4+CD25+ REGULATORY T CELLS IN HEALTH AND DISEASE

  2006cited by this paper
• Cancer stem cells: an old idea--a paradigm shift.

  2006cited by this paper
• BRAF somatic mutations in malignant melanoma and melanocytic naevi

  2006cited by this paper
• Chemotherapy for metastatic melanoma

  2006cited by this paper
• microRNAs exhibit high frequency genomic alterations in human cancer.

  2006cited by this paper
• Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease Outcome

  2006cited by this paper
• Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α

  2006cited by this paper
• The WNT/Beta-catenin pathway in melanoma.

  2006cited by this paper
• Vaccination: role in metastatic melanoma

  2006cited by this paper
• Complete Regression of Large Solid Tumors Using Engineered Drug-Resistant Hematopoietic Cells and Anti-CD137 Immunotherapy

  2006cited by this paper
• Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain

  2006cited by this paper
• A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma

  2006cited by this paper
• Human Melanoma Metastases Express Functional CXCR4

  2006cited by this paper
• Targeting antigens to dendritic cells in vivo.

  2006cited by this paper
• Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma

  2006cited by this paper
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  2006cited by this paper
• Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma

  2006cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Lack of clinical efficacy of imatinib in metastatic melanoma

  2005cited by this paper
• ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.

  2005cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Functional and therapeutic significance of Akt deregulation in malignant melanoma

  2005cited by this paper
• Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.

  2005cited by this paper
• Interleukin-2 for the treatment of melanoma.

  2005cited by this paper
• siRNA, miRNA and HIV: promises and challenges

  2005cited by this paper
• Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

  2005cited by this paper
• A tumorigenic subpopulation with stem cell properties in melanomas.

  2005cited by this paper
• The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

  2005cited by this paper
• The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.

  2005cited by this paper
• Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.

  2005cited by this paper
• Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

  2005cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

  2005cited by this paper
• Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

  2005cited by this paper
• Distinct Structural TCR Repertoires in Naturally Occurring Versus Vaccine-Induced CD8+ T-Cell Responses to the Tumor-Specific Antigen NY-ESO-1

  2005cited by this paper
• PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

  2005cited by this paper
• AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.

  2005cited by this paper
• Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

  2005cited by this paper
• Dendritic cells in melanoma immunotherapy

  2005cited by this paper
• Notch and NOXA-related pathways in melanoma cells.

  2005cited by this paper
• An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Intercavitary Placement of Lymphokine-Activated Killer (LAK) Cells After Resection of Primary Glioblastoma: A Planned Interim Analysis

  2005cited by this paper
• Identification of FGFR2 as a novel melanoma oncogene

  2005cited by this paper
• CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring

  2004cited by this paper
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

  2004cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.

  2004cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

  2004cited by this paper
• Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

  2004cited by this paper
• Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt

  2004cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

  2003cited by this paper
• Determinants of BRAF mutations in primary melanomas.

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Biochemotherapy of melanoma.

  2003cited by this paper
• Selective targeted delivery of TNFalpha to tumor blood vessels.

  2003cited by this paper
• Tannic Acid Is an Inhibitor of CXCL12 (SDF-1α)/CXCR4 with Antiangiogenic Activity

  2003cited by this paper
• Lack of BRAF mutations in uveal melanoma.

  2003cited by this paper

• Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway.

  2019cites this paper
• Gambogenic acid induces cell growth inhibition, cell cycle arrest and metastasis inhibition in choroidal melanoma in a dose-dependent manner.

  2017cites this paper
• The effects of anticancer drugs TSA and GSK on spermatogenesis in male mice.

  2016cites this paper
• A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes

  2015cites this paper
• Multivalent presentation of a hydrolytically stable GM(3) lactone mimetic as modulator of melanoma cells motility and adhesion.

  2013cites this paper
• Specifically targeting ERK1 or ERK2 kills Melanoma cells

  2012cites this paper
• Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management.

  2011cites this paper
• Antiproliferative and proapoptotic actions of okra pectin on B16F10 melanoma cells

  2010cites this paper
• Etude de la résistance à l'anoïkis des cellules de mélanome B16F10 cultivées sur revêtements anti-adhésifs.

  2009cites this paper
• Melanoma: molecular pathogenesis and emerging target therapies (Review).

  2009cites this paper
• New techniques in dermatopathology that help to diagnose and prognosticate melanoma.

  2009cites this paper
• How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer

  2009cites this paper
• Genetically engineered Newcastle disease virus for malignant melanoma therapy

  2009cites this paper
• Cellular signal-specific peptide substrate is essential for the gene delivery system responding to cellular signals.

  2009cites this paper
• BRAFV600E mutation in papillary thyroid carcinoma: a potential target for therapy?

  2009cites this paper
• Tratamento do melanoma maligno

  2009cites this paper
• The sodium pump α1 sub-unit: a disease progression–related target for metastatic melanoma treatment

  2009cites this paper
• Is B-Raf a good therapeutic target for melanoma and other malignancies?

  2008cites this paper
• Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of alpha3 integrin and MMP-2 expression and activity.

  2008cites this paper
• Searching for the Achilles’ heel of melanoma cells: new treatment modalities

  2008cites this paper
• Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma

  2007cites this paper
• Adjuvant therapy of malignant melanoma.

  2002cites this paper
• Adjuvant therapy for cutaneous malignant melanoma.

  1997cites this paper
• The role of adjuvant therapy in melanoma management

  1995cites this paper
• Long term response to chemotherapy in patients with visceral metastatic melanoma.

  1994cites this paper
• World Journal of Surgical Oncology Open Access Extensive Necrosis of Visceral Melanoma Metastases after Immunotherapy

  year unknowncites this paper